Roivant Sciences Ltd (FRA:87S)
€ 11.525 0.15 (1.32%) Market Cap: 8.62 Bil Enterprise Value: 3.56 Bil PE Ratio: 2.21 PB Ratio: 1.78 GF Score: 60/100

Roivant Sciences Ltd at JPMorgan Healthcare Conference Transcript

Jan 09, 2023 / 10:15PM GMT
Release Date Price: €8.27 (+11.76%)
Lut Ming Cheng
JPMorgan Chase & Co, Research Division - Research Analyst

Good afternoon. Thanks for joining us for another session at our 41st Annual JPMorgan Healthcare Conference. I'm Brian Cheng. I'm one of the senior biotech analysts covering Roivant Sciences at the firm. Presenting next is the management team for Roivant. (Operator Instructions) Pass the stage to Roivant's CEO, Mat Gline for the presentation. Matt, welcome, and the stage is yours.

Matthew Gline
Roivant Sciences Ltd. - CEO & Director

Thank you, Brian. Good afternoon, everybody. Thank you for coming. Excited to present and then take some questions, and yes, looking forward to it. So we're going to make some forward-looking statements for more information. You can consult our forward-looking statements and disclaimers.

So I'm going to start on Page 3 for those following along online. I'm not going to spend a ton of time on the past, but I just want to reflect, 2022 has actually been a very busy year for us. We launched our first wholly owned product in VTAMA, which got

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot